Cargando…

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer

Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xianmeng, Xia, Daqing, Jiang, Xuqin, Cao, Lejie, Ryu, Jay H., Hu, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663455/
https://www.ncbi.nlm.nih.gov/pubmed/36386178
http://dx.doi.org/10.3389/fphar.2022.944685
_version_ 1784830879589203968
author Chen, Xianmeng
Xia, Daqing
Jiang, Xuqin
Cao, Lejie
Ryu, Jay H.
Hu, Xiaowen
author_facet Chen, Xianmeng
Xia, Daqing
Jiang, Xuqin
Cao, Lejie
Ryu, Jay H.
Hu, Xiaowen
author_sort Chen, Xianmeng
collection PubMed
description Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with ALK-rearranged advanced lung adenocarcinoma who developed interstitial lung disease associated with alectinib therapy. At 102-day of treatment, chest CT revealed scattered ground glass opacities (GGOs) involving both lungs. Since she was asymptomatic and alectinib provided a beneficial tumor treatment response, alectinib therapy was continued. However, 2 months later, she presented with progressive dyspnea and diffuse GGOs on chest computed tomography. There was no evidence for infection or other etiologies for her lung complication. Alectinib was discontinued and steroid therapy was initiated which was followed by improvement in respiratory symptoms and chest CT findings; DRP was diagnosed. Although rare, alectinib therapy can cause DRP of indolent onset.
format Online
Article
Text
id pubmed-9663455
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96634552022-11-15 Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer Chen, Xianmeng Xia, Daqing Jiang, Xuqin Cao, Lejie Ryu, Jay H. Hu, Xiaowen Front Pharmacol Pharmacology Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with ALK-rearranged advanced lung adenocarcinoma who developed interstitial lung disease associated with alectinib therapy. At 102-day of treatment, chest CT revealed scattered ground glass opacities (GGOs) involving both lungs. Since she was asymptomatic and alectinib provided a beneficial tumor treatment response, alectinib therapy was continued. However, 2 months later, she presented with progressive dyspnea and diffuse GGOs on chest computed tomography. There was no evidence for infection or other etiologies for her lung complication. Alectinib was discontinued and steroid therapy was initiated which was followed by improvement in respiratory symptoms and chest CT findings; DRP was diagnosed. Although rare, alectinib therapy can cause DRP of indolent onset. Frontiers Media S.A. 2022-11-01 /pmc/articles/PMC9663455/ /pubmed/36386178 http://dx.doi.org/10.3389/fphar.2022.944685 Text en Copyright © 2022 Chen, Xia, Jiang, Cao, Ryu and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Xianmeng
Xia, Daqing
Jiang, Xuqin
Cao, Lejie
Ryu, Jay H.
Hu, Xiaowen
Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
title Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
title_full Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
title_fullStr Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
title_full_unstemmed Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
title_short Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
title_sort case report: indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663455/
https://www.ncbi.nlm.nih.gov/pubmed/36386178
http://dx.doi.org/10.3389/fphar.2022.944685
work_keys_str_mv AT chenxianmeng casereportindolentdrugrelatedpneumonitiswithalectinibtherapyinthetreatmentofnonsmallcelllungcancer
AT xiadaqing casereportindolentdrugrelatedpneumonitiswithalectinibtherapyinthetreatmentofnonsmallcelllungcancer
AT jiangxuqin casereportindolentdrugrelatedpneumonitiswithalectinibtherapyinthetreatmentofnonsmallcelllungcancer
AT caolejie casereportindolentdrugrelatedpneumonitiswithalectinibtherapyinthetreatmentofnonsmallcelllungcancer
AT ryujayh casereportindolentdrugrelatedpneumonitiswithalectinibtherapyinthetreatmentofnonsmallcelllungcancer
AT huxiaowen casereportindolentdrugrelatedpneumonitiswithalectinibtherapyinthetreatmentofnonsmallcelllungcancer